ا ھ/ د / CASE 4-31673A



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 335541349U5

7/20

7/25/03 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

AULT ET AL.

APPLICATION NO: 10/006,311 FILED: DECEMBER 4, 2001

FOR: PHARMACEUTICAL COMPOSITIONS FOR THE ORAL DELIVERY

OF PHARMACOLOGICALLY ACTIVE AGENTS

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Office Action for Restriction Requirement dated June 26, 2003, having a period for response set to expire July 26, 2003, making this response timely filed, Applicants respectfully request the following amendment for election of claims and subject matter be entered and the claims considered in light thereof.

## RESTRICTION REQUIREMENT:

The Examiner has required restriction of the Examination of the above-identified application, under 35 U.S.C. 121, to one of the following inventions as specified by the Examiner:

- I. Claims 1-11 drawn to a product, classified in class 435, subclass various.
- II. Claim 12, drawn to a first method of using the product, classified in class 514, subclass various.
- III. Claims 13 and 14, drawn to a second method of using the product, classified in class 424, subclass various.

Additionally, the Examiner has required that the Applicants elect a single disclosed species for prosecution on the merits to which the claims will be restricted if no generic claim is found to be